Evidence map›Paper›PMID 29333130›Full record

ArticleEXCLI journal2017

An

Ibrahim Malami, Aliyu Muhammad, Imaobong C Etti, Peter M Waziri, Alhassan M Alhassan

Abstract read
In one paragraph

Article in EXCLI journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ibrahim MalamiFaculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.
Aliyu MuhammadDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria.
Imaobong C EttiDepartment of Pharmacology and Toxicology, Universiti of Uyo, Uyo, Nigeria.
Peter M WaziriDepartment of Biochemistry, Kaduna State University, Kaduna, Nigeria.
Alhassan M AlhassanFaculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

R273H mutant p53 is a DNA-contact mutant that renders p53 dysfunctional due to a single substitution of Arg273 for His273. Rescuing R273 mutant p53 implies that a competent molecule would have to bind to the site of DNA-contact hot spots to complement the loss of contact with the DNA-binding domain. Here, curcumin, flavokawain B, and alpinetin were docked against the crystal structure of R273H mutant p53

Indexed as

alpinetincurcuminDNA-binding domainflavokawain Bmolecular docking simulationR273H mutant p53

Identifiers

PMID29333130
PMCPMC5763090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.